MDXH Company Profile and Key Details

MDXH has shown mixed momentum, gaining 4.37% over the past week and -10.72% over the past quarter, though year-to-date performance is up 0.28%. Short-term trend indicators are bearishly aligned (SMA20 0.01%, SMA50 1.01%, SMA200 8.27%). The stock’s 14-day RSI is 49.14 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.4% below its high and over 162.96% above its low. Average 10-day trading volume of 148.37 thousand shares is slightly above the 3-month average of 127.92 thousand, indicating heightened recent market interest.

MDxHealth S.A. generated EPS of -$0.64 over the past year. Five-year average earnings growth is 29.99%. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.13. Next year's EPS is expected at $30.90. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $7.00. The high target offers 168.66% upside. The low target suggests 108.96% downside. The mean target is $7.50. This offers 123.88% upside. MDxHealth S.A. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 33.33%. The prior quarter beat by 15.38%. Over the last six quarters, Apple has recorded several small beats. These include 19.23% in August 21, 2024.

MDxHealth S.A. has 49.50 million shares outstanding. The public float is 35.02 million shares, elevated short interest at 0.29% of float. This equals 118.95 thousand shares. The short ratio is 2.07 days. Institutional investors hold 50.31% of the float. Insiders own 13.22%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

MDxHealth S.A. (NASDAQ:MDXH) closed at $3.31 USD, losing -$0.11 (-3.22%) from the previous close of $3.42. The stock is currently mid-range between its 52-week high and low $1.35 and $5.33. With a market capitalization of about $170.02 million, MDxHealth S.A. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.38). Key stats such as the average daily volume over the past year has been around 128.98 thousand shares, in line with its 52-week average. Headquartered in Herstal, None, MDxHealth S.A. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Michael K. McGarrity, the company employs approximately 312 people and listed since November 04, 2021. MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally.

MDxHealth S.A. trades at a P/E ratio of -4.92, slightly below the S&P 500 average, with a price-to-sales ratio of 1.69 and a price-to-book ratio of -182.79 indicating negative book value, which may reflect financial stress. The P/FCF stands at -15.41, also below market averages.

MDxHealth S.A. (NASDAQ:MDXH) shares are flat 0.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MDxHealth S.A. trading at a premium to the broader market with a P/E of -4.92. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.67, suggesting 188.66% upside. Our AI forecast model points to short-term weakness (-1.49% over two weeks), a medium-term rise (44.78% over three months), and a longer-term gain (468.06% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MDxHealth S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.49%, with price expected at $3.30 by March 17, 2026, within a range of $3.13 to $3.46 3-Month Outlook: Projected rise of 44.78%, reaching $4.85 by June 01, 2026, with a range of $4.22 to $5.30. 1-Year Outlook: Projected gain of 468.06%, with price at $19.03 by March 03, 2027, within a range of $18.70 to $24.19.